Determination of methotrexate, several pteridines, and creatinine in human urine, previous oxidation with potassium permanganate, using HPLC with photometric and fluorimetric serial detection

被引:69
作者
Merás, ID [1 ]
Mansilla, AE [1 ]
Gómez, MJR [1 ]
机构
[1] Univ Extremadura, Dept Analyt Chem, E-06071 Badajoz, Spain
关键词
HPLC; photometric detection; fluorimetric detection; methotrexate; pteridines; creatinine;
D O I
10.1016/j.ab.2005.07.038
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A novel HPLC method, using UV and fluorimetric serial detection, for the simultaneous determination of methotrexate (MTX), five disease marker pteridines, and the reference metabolic subproduct creatinine (CREA) in human urine was established. A previous oxidation process using 10(-3) M KMnO4 (pH 5.0) and 35 min of oxidation time was necessary to transform the analytes in the highly fluorescent pteridinic rings. CREA was not affected by the oxidative medium. Using Tris-HCl/NaCl buffer solution (pH 6.6) as mobile phase, MTX and the assayed pteridines were monitored by fluorescence at lambda(em) = 444 nm and lambda(ex) = 280 nm and creatinine was monitored by absorption measurements at lambda(abs) = 230 nm. All components were well resolved in approximately 7 min. Detection limits, according the criteria of Clayton and co-workers, were 10 ng ml(-1) for MTX, less than 1 ng ml(-1) for all of the pteridines, and 4 mu g ml(-1) for CREA. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 20 条
[1]  
[Anonymous], 1965, Statistical Theory and Methodology in Science and Engineering
[2]  
BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
[3]  
2-I
[4]   DETECTION LIMITS WITH SPECIFIED ASSURANCE PROBABILITIES [J].
CLAYTON, CA ;
HINES, JW ;
ELKINS, PD .
ANALYTICAL CHEMISTRY, 1987, 59 (20) :2506-2514
[5]   Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum [J].
Espinosa-Mansilla, A ;
Merás, ID ;
Madera, AZ ;
Pedano, L ;
Ferreyra, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (05) :851-858
[6]  
Espinosa-Mansilla A, 2001, CHROMATOGRAPHIA, V53, P510
[7]   ANTIFOLATE ANALOGS - MECHANISM OF ACTION, ANALYTICAL METHODOLOGY, AND CLINICAL EFFICACY [J].
FLEISHER, M .
THERAPEUTIC DRUG MONITORING, 1993, 15 (06) :521-526
[8]   Pteridine analysis in urine by capillary electrophoresis using laser-induced fluorescence detection [J].
Han, FT ;
Huynh, BH ;
Shi, HL ;
Lin, BC ;
Ma, YF .
ANALYTICAL CHEMISTRY, 1999, 71 (07) :1265-1269
[9]  
KATRITZKY AR, 1984, COMPREHENSIVE HETERO, V3
[10]  
KIMURA K, 1986, METHOTREXATE CANC TH